Literature DB >> 22761329

Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.

Sushmita Das1, Mukta Rani, Krishna Pandey, Ganesh Chandra Sahoo, Vidya Nand Rabidas, Dharmendra Singh, Pradeep Das.   

Abstract

OBJECTIVES: To evaluate the in vitro activity of antileishmanial drugs, paromomycin and miltefosine, to generate Th-1-biased immunomodulation in hosts against intracellular Leishmania donovani.
METHODS: In silico protein-ligand interaction and in vitro drug-cell interaction assays were performed. Interaction assays of TLR4-deficient HEK293 cells and HEK293 cells engineered to express either TLR4 or TLR2 with different concentrations of miltefosine and/or paromomycin sulphate were performed for 48 h. Differentially transfected human peripheral blood monocyte-derived macrophages (PBMFs) were treated with the drugs, and nuclear factor (NF)-κB promoter activity was measured using a κB-luciferase reporter construct. PBMFs were infected with L. donovani. Cultures were incubated with miltefosine or paromomycin sulphate over different concentrations, as mono-treatment or combined. The in vitro antileishmanial effect of the drugs on macrophage-bound L. donovani amastigotes was measured in terms of parasite killing and production of tumour necrosis factor-α (TNF-α) and nitric oxide.
RESULTS: Computational studies reveal that paromomycin and miltefosine interact with TLR4. Both drugs, as monotherapy or in combination, induce release of TNF-α and nitric oxide in a TLR4-dependent manner. Interestingly, the TLR4-dependent action of the drugs leads to NF-κB promoter activation through MyD88. In vitro, both the drugs kill macrophage-bound L. donovani by inducing release of TNF-α and nitric oxide in a TLR4-dependent manner.
CONCLUSIONS: The in vitro activity of paromomycin and miltefosine against host cells is TLR4 dependent. This has implications for: (i) evaluation of in vitro activity of combinational antileishmanial therapy; (ii) the evaluation of drug susceptibility of clinical isolates; and (iii) the standardization of in vitro antileishmanial assays for determining toxicity in hosts.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761329     DOI: 10.1093/jac/dks220

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors:  Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-17       Impact factor: 4.481

2.  New trends in aminoglycosides use.

Authors:  Marina Y Fosso; Yijia Li; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

3.  TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis.

Authors:  Sushmita Das; Mukta Rani; Vidyanand Rabidas; Krishna Pandey; Ganesh Chandra Sahoo; Pradeep Das
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

4.  Leishmanicidal activities of novel methylseleno-imidocarbamates.

Authors:  Celia Fernández-Rubio; Daphne Campbell; Andrés Vacas; Elena Ibañez; Esther Moreno; Socorro Espuelas; Alfonso Calvo; Juan Antonio Palop; Daniel Plano; Carmen Sanmartin; Paul A Nguewa
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

5.  Leishmania donovani Secretory Mevalonate Kinase Regulates Host Immune Response and Facilitates Phagocytosis.

Authors:  Tanvir Bamra; Taj Shafi; Sushmita Das; Manjay Kumar; Manas Ranjan Dikhit; Ajay Kumar; Ashish Kumar; Kumar Abhishek; Krishna Pandey; Abhik Sen; Pradeep Das
Journal:  Front Cell Infect Microbiol       Date:  2021-04-26       Impact factor: 5.293

6.  The involvement of TLR2 and TLR4 in cytokine and nitric oxide production in visceral leishmaniasis patients before and after treatment with anti-leishmanial drugs.

Authors:  Mariana Gatto; Mariana Miziara de Abreu; Karen Ingrid Tasca; Marjorie de Assis Golim; Laura Denise Mendes da Silva; José Cláudio Simão; Carlos Magno Castelo Branco Fortaleza; Ângela Maria Victoriano de Campos Soares; Sueli Aparecida Calvi
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

7.  Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani.

Authors:  Manas R Dikhit; Bidyut Purkait; Ruby Singh; Bikash Ranjan Sahoo; Ashish Kumar; Rajiv K Kar; Md Yousuf Ansari; Savita Saini; Kumar Abhishek; Ganesh C Sahoo; Sushmita Das; Pradeep Das
Journal:  Drug Des Devel Ther       Date:  2016-05-26       Impact factor: 4.162

8.  The Effects of Polyhexamethylene Biguanide (PHMB) and TLR Agonists Alone or as Polyplex Nanoparticles against Leishmania infantum Promastigotes and Amastigotes.

Authors:  Pamela Martínez-Orellana; Marta Baxarias; Liam Good; Laia Solano-Gallego
Journal:  Vet Sci       Date:  2020-11-13

9.  TLR4 and TLR9 polymorphism: Probable role in susceptibility among the population of Bihar for Indian visceral leishmaniasis.

Authors:  Abhishek Mandal; Manish Kumar; Ashish Kumar; Abhik Sen; Pradeep Das; Sushmita Das
Journal:  Innate Immun       Date:  2021-04-28       Impact factor: 2.680

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.